The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Opioid Induced Constipation (OIC) Drug-Global Market Insights and Sales Trends 2024
Synopsis
Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.
The global Opioid Induced Constipation (OIC) Drug market size is expected to reach US$ 3490.4 million by 2029, growing at a CAGR of 4.6% from 2023 to 2029. The market is mainly driven by the significant applications of Opioid Induced Constipation (OIC) Drug in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, are propelling Opioid Induced Constipation (OIC) Drug market. Lubiprostone, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Methyl Naltrexone Bromide segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Distribution Channel. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Opioid Induced Constipation (OIC) Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Opioid Induced Constipation (OIC) Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Opioid Induced Constipation (OIC) Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Opioid Induced Constipation (OIC) Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Opioid Induced Constipation (OIC) Drug covered in this report include Ironwood Pharmaceuticals, Daiichi Sankyo Co, Pfizer, Progenics Pharmaceuticals, Shionogi &, Allergan, Nektar Therapeutics, Purdue Pharma and S.L.A. Pharma, etc.
The global Opioid Induced Constipation (OIC) Drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Ironwood Pharmaceuticals
Daiichi Sankyo Co
Pfizer
Progenics Pharmaceuticals
Shionogi &
Allergan
Nektar Therapeutics
Purdue Pharma
S.L.A. Pharma
Mundipharma International Limited
Ono Pharmaceutical
Takeda Pharmaceutical Company Limited
Theravance Biopharma
Bausch Health
Cosmo Pharmaceuticals SA
Daewoong Pharmaceutical
C.B. Fleet Company
Sucampo Pharmaceuticals
Global Opioid Induced Constipation (OIC) Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Opioid Induced Constipation (OIC) Drug market, Segment by Type:
Lubiprostone
Methyl Naltrexone Bromide
Naldemedine
Alvimopan
Other
Global Opioid Induced Constipation (OIC) Drug market, by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Opioid Induced Constipation (OIC) Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Opioid Induced Constipation (OIC) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Distribution Channel, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.
The global Opioid Induced Constipation (OIC) Drug market size is expected to reach US$ 3490.4 million by 2029, growing at a CAGR of 4.6% from 2023 to 2029. The market is mainly driven by the significant applications of Opioid Induced Constipation (OIC) Drug in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, are propelling Opioid Induced Constipation (OIC) Drug market. Lubiprostone, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Methyl Naltrexone Bromide segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Distribution Channel. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Opioid Induced Constipation (OIC) Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Opioid Induced Constipation (OIC) Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Opioid Induced Constipation (OIC) Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Opioid Induced Constipation (OIC) Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Opioid Induced Constipation (OIC) Drug covered in this report include Ironwood Pharmaceuticals, Daiichi Sankyo Co, Pfizer, Progenics Pharmaceuticals, Shionogi &, Allergan, Nektar Therapeutics, Purdue Pharma and S.L.A. Pharma, etc.
The global Opioid Induced Constipation (OIC) Drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Ironwood Pharmaceuticals
Daiichi Sankyo Co
Pfizer
Progenics Pharmaceuticals
Shionogi &
Allergan
Nektar Therapeutics
Purdue Pharma
S.L.A. Pharma
Mundipharma International Limited
Ono Pharmaceutical
Takeda Pharmaceutical Company Limited
Theravance Biopharma
Bausch Health
Cosmo Pharmaceuticals SA
Daewoong Pharmaceutical
C.B. Fleet Company
Sucampo Pharmaceuticals
Global Opioid Induced Constipation (OIC) Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Opioid Induced Constipation (OIC) Drug market, Segment by Type:
Lubiprostone
Methyl Naltrexone Bromide
Naldemedine
Alvimopan
Other
Global Opioid Induced Constipation (OIC) Drug market, by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Opioid Induced Constipation (OIC) Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Opioid Induced Constipation (OIC) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Distribution Channel, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Opioid Induced Constipation (OIC) Drug Market Overview
1.1 Opioid Induced Constipation (OIC) Drug Product Overview
1.2 Opioid Induced Constipation (OIC) Drug Market Segment by Type
1.2.1 Lubiprostone
1.2.2 Methyl Naltrexone Bromide
1.2.3 Naldemedine
1.2.4 Alvimopan
1.2.5 Other
1.3 Global Opioid Induced Constipation (OIC) Drug Market Size by Type
1.3.1 Global Opioid Induced Constipation (OIC) Drug Market Size Overview by Type (2018-2029)
1.3.2 Global Opioid Induced Constipation (OIC) Drug Historic Market Size Review by Type (2018-2023)
1.3.3 Global Opioid Induced Constipation (OIC) Drug Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Opioid Induced Constipation (OIC) Drug Sales Breakdown by Type (2018-2023)
1.4.2 Europe Opioid Induced Constipation (OIC) Drug Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Opioid Induced Constipation (OIC) Drug Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales Breakdown by Type (2018-2023)
2 Global Opioid Induced Constipation (OIC) Drug Market Competition by Company
2.1 Global Top Players by Opioid Induced Constipation (OIC) Drug Sales (2018-2023)
2.2 Global Top Players by Opioid Induced Constipation (OIC) Drug Revenue (2018-2023)
2.3 Global Top Players by Opioid Induced Constipation (OIC) Drug Price (2018-2023)
2.4 Global Top Manufacturers Opioid Induced Constipation (OIC) Drug Manufacturing Base Distribution, Sales Area, Product Type
2.5 Opioid Induced Constipation (OIC) Drug Market Competitive Situation and Trends
2.5.1 Opioid Induced Constipation (OIC) Drug Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Opioid Induced Constipation (OIC) Drug Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Opioid Induced Constipation (OIC) Drug as of 2022)
2.7 Date of Key Manufacturers Enter into Opioid Induced Constipation (OIC) Drug Market
2.8 Key Manufacturers Opioid Induced Constipation (OIC) Drug Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Opioid Induced Constipation (OIC) Drug Status and Outlook by Region
3.1 Global Opioid Induced Constipation (OIC) Drug Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Opioid Induced Constipation (OIC) Drug Historic Market Size by Region
3.2.1 Global Opioid Induced Constipation (OIC) Drug Sales in Volume by Region (2018-2023)
3.2.2 Global Opioid Induced Constipation (OIC) Drug Sales in Value by Region (2018-2023)
3.2.3 Global Opioid Induced Constipation (OIC) Drug Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Opioid Induced Constipation (OIC) Drug Forecasted Market Size by Region
3.3.1 Global Opioid Induced Constipation (OIC) Drug Sales in Volume by Region (2024-2029)
3.3.2 Global Opioid Induced Constipation (OIC) Drug Sales in Value by Region (2024-2029)
3.3.3 Global Opioid Induced Constipation (OIC) Drug Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Opioid Induced Constipation (OIC) Drug by Distribution Channel
4.1 Opioid Induced Constipation (OIC) Drug Market Segment by Distribution Channel
4.1.1 Hospital Pharmacies
4.1.2 Retail Pharmacies
4.1.3 Online Pharmacies
4.2 Global Opioid Induced Constipation (OIC) Drug Market Size by Distribution Channel
4.2.1 Global Opioid Induced Constipation (OIC) Drug Market Size Overview by Distribution Channel (2018-2029)
4.2.2 Global Opioid Induced Constipation (OIC) Drug Historic Market Size Review by Distribution Channel (2018-2023)
4.2.3 Global Opioid Induced Constipation (OIC) Drug Forecasted Market Size by Distribution Channel (2024-2029)
4.3 Key Regions Market Size Segment by Distribution Channel
4.3.1 North America Opioid Induced Constipation (OIC) Drug Sales Breakdown by Distribution Channel (2018-2023)
4.3.2 Europe Opioid Induced Constipation (OIC) Drug Sales Breakdown by Distribution Channel (2018-2023)
4.3.3 Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales Breakdown by Distribution Channel (2018-2023)
4.3.4 Latin America Opioid Induced Constipation (OIC) Drug Sales Breakdown by Distribution Channel (2018-2023)
4.3.5 Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales Breakdown by Distribution Channel (2018-2023)
5 North America Opioid Induced Constipation (OIC) Drug by Country
5.1 North America Opioid Induced Constipation (OIC) Drug Historic Market Size by Country
5.1.1 North America Opioid Induced Constipation (OIC) Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Opioid Induced Constipation (OIC) Drug Sales in Volume by Country (2018-2023)
5.1.3 North America Opioid Induced Constipation (OIC) Drug Sales in Value by Country (2018-2023)
5.2 North America Opioid Induced Constipation (OIC) Drug Forecasted Market Size by Country
5.2.1 North America Opioid Induced Constipation (OIC) Drug Sales in Volume by Country (2024-2029)
5.2.2 North America Opioid Induced Constipation (OIC) Drug Sales in Value by Country (2024-2029)
6 Europe Opioid Induced Constipation (OIC) Drug by Country
6.1 Europe Opioid Induced Constipation (OIC) Drug Historic Market Size by Country
6.1.1 Europe Opioid Induced Constipation (OIC) Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Opioid Induced Constipation (OIC) Drug Sales in Volume by Country (2018-2023)
6.1.3 Europe Opioid Induced Constipation (OIC) Drug Sales in Value by Country (2018-2023)
6.2 Europe Opioid Induced Constipation (OIC) Drug Forecasted Market Size by Country
6.2.1 Europe Opioid Induced Constipation (OIC) Drug Sales in Volume by Country (2024-2029)
6.2.2 Europe Opioid Induced Constipation (OIC) Drug Sales in Value by Country (2024-2029)
7 Asia-Pacific Opioid Induced Constipation (OIC) Drug by Region
7.1 Asia-Pacific Opioid Induced Constipation (OIC) Drug Historic Market Size by Region
7.1.1 Asia-Pacific Opioid Induced Constipation (OIC) Drug Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Opioid Induced Constipation (OIC) Drug Forecasted Market Size by Region
7.2.1 Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales in Value by Region (2024-2029)
8 Latin America Opioid Induced Constipation (OIC) Drug by Country
8.1 Latin America Opioid Induced Constipation (OIC) Drug Historic Market Size by Country
8.1.1 Latin America Opioid Induced Constipation (OIC) Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Opioid Induced Constipation (OIC) Drug Sales in Volume by Country (2018-2023)
8.1.3 Latin America Opioid Induced Constipation (OIC) Drug Sales in Value by Country (2018-2023)
8.2 Latin America Opioid Induced Constipation (OIC) Drug Forecasted Market Size by Country
8.2.1 Latin America Opioid Induced Constipation (OIC) Drug Sales in Volume by Country (2024-2029)
8.2.2 Latin America Opioid Induced Constipation (OIC) Drug Sales in Value by Country (2024-2029)
9 Middle East and Africa Opioid Induced Constipation (OIC) Drug by Country
9.1 Middle East and Africa Opioid Induced Constipation (OIC) Drug Historic Market Size by Country
9.1.1 Middle East and Africa Opioid Induced Constipation (OIC) Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Opioid Induced Constipation (OIC) Drug Forecasted Market Size by Country
9.2.1 Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Ironwood Pharmaceuticals
10.1.1 Ironwood Pharmaceuticals Company Information
10.1.2 Ironwood Pharmaceuticals Introduction and Business Overview
10.1.3 Ironwood Pharmaceuticals Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Ironwood Pharmaceuticals Opioid Induced Constipation (OIC) Drug Products Offered
10.1.5 Ironwood Pharmaceuticals Recent Development
10.2 Daiichi Sankyo Co
10.2.1 Daiichi Sankyo Co Company Information
10.2.2 Daiichi Sankyo Co Introduction and Business Overview
10.2.3 Daiichi Sankyo Co Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Daiichi Sankyo Co Opioid Induced Constipation (OIC) Drug Products Offered
10.2.5 Daiichi Sankyo Co Recent Development
10.3 Pfizer
10.3.1 Pfizer Company Information
10.3.2 Pfizer Introduction and Business Overview
10.3.3 Pfizer Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Pfizer Opioid Induced Constipation (OIC) Drug Products Offered
10.3.5 Pfizer Recent Development
10.4 Progenics Pharmaceuticals
10.4.1 Progenics Pharmaceuticals Company Information
10.4.2 Progenics Pharmaceuticals Introduction and Business Overview
10.4.3 Progenics Pharmaceuticals Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Progenics Pharmaceuticals Opioid Induced Constipation (OIC) Drug Products Offered
10.4.5 Progenics Pharmaceuticals Recent Development
10.5 Shionogi &
10.5.1 Shionogi & Company Information
10.5.2 Shionogi & Introduction and Business Overview
10.5.3 Shionogi & Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Shionogi & Opioid Induced Constipation (OIC) Drug Products Offered
10.5.5 Shionogi & Recent Development
10.6 Allergan
10.6.1 Allergan Company Information
10.6.2 Allergan Introduction and Business Overview
10.6.3 Allergan Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Allergan Opioid Induced Constipation (OIC) Drug Products Offered
10.6.5 Allergan Recent Development
10.7 Nektar Therapeutics
10.7.1 Nektar Therapeutics Company Information
10.7.2 Nektar Therapeutics Introduction and Business Overview
10.7.3 Nektar Therapeutics Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Nektar Therapeutics Opioid Induced Constipation (OIC) Drug Products Offered
10.7.5 Nektar Therapeutics Recent Development
10.8 Purdue Pharma
10.8.1 Purdue Pharma Company Information
10.8.2 Purdue Pharma Introduction and Business Overview
10.8.3 Purdue Pharma Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Purdue Pharma Opioid Induced Constipation (OIC) Drug Products Offered
10.8.5 Purdue Pharma Recent Development
10.9 S.L.A. Pharma
10.9.1 S.L.A. Pharma Company Information
10.9.2 S.L.A. Pharma Introduction and Business Overview
10.9.3 S.L.A. Pharma Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)
10.9.4 S.L.A. Pharma Opioid Induced Constipation (OIC) Drug Products Offered
10.9.5 S.L.A. Pharma Recent Development
10.10 Mundipharma International Limited
10.10.1 Mundipharma International Limited Company Information
10.10.2 Mundipharma International Limited Introduction and Business Overview
10.10.3 Mundipharma International Limited Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Mundipharma International Limited Opioid Induced Constipation (OIC) Drug Products Offered
10.10.5 Mundipharma International Limited Recent Development
10.11 Ono Pharmaceutical
10.11.1 Ono Pharmaceutical Company Information
10.11.2 Ono Pharmaceutical Introduction and Business Overview
10.11.3 Ono Pharmaceutical Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Ono Pharmaceutical Opioid Induced Constipation (OIC) Drug Products Offered
10.11.5 Ono Pharmaceutical Recent Development
10.12 Takeda Pharmaceutical Company Limited
10.12.1 Takeda Pharmaceutical Company Limited Company Information
10.12.2 Takeda Pharmaceutical Company Limited Introduction and Business Overview
10.12.3 Takeda Pharmaceutical Company Limited Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)
10.12.4 Takeda Pharmaceutical Company Limited Opioid Induced Constipation (OIC) Drug Products Offered
10.12.5 Takeda Pharmaceutical Company Limited Recent Development
10.13 Theravance Biopharma
10.13.1 Theravance Biopharma Company Information
10.13.2 Theravance Biopharma Introduction and Business Overview
10.13.3 Theravance Biopharma Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)
10.13.4 Theravance Biopharma Opioid Induced Constipation (OIC) Drug Products Offered
10.13.5 Theravance Biopharma Recent Development
10.14 Bausch Health
10.14.1 Bausch Health Company Information
10.14.2 Bausch Health Introduction and Business Overview
10.14.3 Bausch Health Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)
10.14.4 Bausch Health Opioid Induced Constipation (OIC) Drug Products Offered
10.14.5 Bausch Health Recent Development
10.15 Cosmo Pharmaceuticals SA
10.15.1 Cosmo Pharmaceuticals SA Company Information
10.15.2 Cosmo Pharmaceuticals SA Introduction and Business Overview
10.15.3 Cosmo Pharmaceuticals SA Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)
10.15.4 Cosmo Pharmaceuticals SA Opioid Induced Constipation (OIC) Drug Products Offered
10.15.5 Cosmo Pharmaceuticals SA Recent Development
10.16 Daewoong Pharmaceutical
10.16.1 Daewoong Pharmaceutical Company Information
10.16.2 Daewoong Pharmaceutical Introduction and Business Overview
10.16.3 Daewoong Pharmaceutical Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)
10.16.4 Daewoong Pharmaceutical Opioid Induced Constipation (OIC) Drug Products Offered
10.16.5 Daewoong Pharmaceutical Recent Development
10.17 C.B. Fleet Company
10.17.1 C.B. Fleet Company Company Information
10.17.2 C.B. Fleet Company Introduction and Business Overview
10.17.3 C.B. Fleet Company Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)
10.17.4 C.B. Fleet Company Opioid Induced Constipation (OIC) Drug Products Offered
10.17.5 C.B. Fleet Company Recent Development
10.18 Sucampo Pharmaceuticals
10.18.1 Sucampo Pharmaceuticals Company Information
10.18.2 Sucampo Pharmaceuticals Introduction and Business Overview
10.18.3 Sucampo Pharmaceuticals Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2018-2023)
10.18.4 Sucampo Pharmaceuticals Opioid Induced Constipation (OIC) Drug Products Offered
10.18.5 Sucampo Pharmaceuticals Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Opioid Induced Constipation (OIC) Drug Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Opioid Induced Constipation (OIC) Drug Industrial Chain Analysis
11.4 Opioid Induced Constipation (OIC) Drug Market Dynamics
11.4.1 Opioid Induced Constipation (OIC) Drug Industry Trends
11.4.2 Opioid Induced Constipation (OIC) Drug Market Drivers
11.4.3 Opioid Induced Constipation (OIC) Drug Market Challenges
11.4.4 Opioid Induced Constipation (OIC) Drug Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Opioid Induced Constipation (OIC) Drug Distributors
12.3 Opioid Induced Constipation (OIC) Drug Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
